search
Back to results

Inhaled Budesonide for Altitude Illness Prevention

Primary Purpose

Altitude Sickness

Status
Withdrawn
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Budesonide
Placebo
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Altitude Sickness

Eligibility Criteria

21 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • healthy, altitude naive, 21-40 years old

Exclusion Criteria:

  • smokers
  • pregnancy
  • hx of asthma
  • current inhaled steroid use
  • those with diseases or disorders known to be affected by hypoxia or the drugs used in this study such as

    • migraine or other chronic headaches,
    • sickle cell trait or disease, or
    • diabetes
  • history of significant head injury or seizures
  • taking any medication (over-the-counter or prescription) or herbal supplements
  • a known hypersensitivity reaction to budesonide
  • inability to be headache-free when consuming the amount of caffeine in two six ounce cups of coffee or less per day
  • exposure to high altitude above 2000m in the previous 1 month or
  • those who have been on an airline flight over six hours (Airplane cabins are pressurized to an elevation that can approximate exposure to high altitude)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    Budesonide

    Placebo

    Arm Description

    Will participate in all study activities but will receive budesonide.

    Will participate in all study activities but will receive placebo.

    Outcomes

    Primary Outcome Measures

    Changes in Inflammation
    Analysis to compare activity in pro-inflammatory pathways and activity in anti-permeability pathways, as measured by serum markers, between budesonide and placebo.
    Incidence of Acute Mountain Sickness (AMS)
    Comparison of incidence and severity of acute mountain sickness between budesonide and placebo.
    Changes in Gene regulation
    Comparison of gene regulation involved in acclimatization and altitude illness.

    Secondary Outcome Measures

    Full Information

    First Posted
    October 19, 2016
    Last Updated
    March 9, 2017
    Sponsor
    University of Colorado, Denver
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02941510
    Brief Title
    Inhaled Budesonide for Altitude Illness Prevention
    Official Title
    Inhaled Budesonide for Altitude Illness Prevention
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2017
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Stopped prior to enrollment per PI and DSMB decision.
    Study Start Date
    March 6, 2017 (Actual)
    Primary Completion Date
    March 6, 2017 (Actual)
    Study Completion Date
    March 6, 2017 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University of Colorado, Denver

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    A randomized, double-blinded study administering budesonide, a medication to reduce inflammation in the lungs, to healthy volunteers to examine effects on altitude illness prevention by spending 18 hours overnight at 14,000 ft elevation.
    Detailed Description
    A randomized, double-blinded study will be conducted to validate the results of previous literature on the use of budesonide in the prevention of altitude sickness. It will be conducted using healthy participants overseen by experienced wilderness medicine and altitude researchers from the Altitude Research Center at University of Colorado Denver. Participants will be recruited from the Denver community and prescreened for eligibility via phone. 100 participants, after consenting, will have baseline data and blood collected and will begin budesonide therapy 72 hours prior to being taken from Denver to Pikes Peak, where they will be observed at altitude for 18 hours. Patients will have the opportunity to withdraw consent at any time and will be monitored continuously by physician-researchers. Data collection and blood draws will be performed at specific time points and analyzed for efficacy of budesonide vs. placebo in the incidence of altitude sickness.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Altitude Sickness

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Budesonide
    Arm Type
    Experimental
    Arm Description
    Will participate in all study activities but will receive budesonide.
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    Will participate in all study activities but will receive placebo.
    Intervention Type
    Drug
    Intervention Name(s)
    Budesonide
    Intervention Description
    Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
    Intervention Type
    Other
    Intervention Name(s)
    Placebo
    Intervention Description
    Subject(s) will participate in all study activities but will receive placebo.
    Primary Outcome Measure Information:
    Title
    Changes in Inflammation
    Description
    Analysis to compare activity in pro-inflammatory pathways and activity in anti-permeability pathways, as measured by serum markers, between budesonide and placebo.
    Time Frame
    During 18 hours at elevation compared to baseline.
    Title
    Incidence of Acute Mountain Sickness (AMS)
    Description
    Comparison of incidence and severity of acute mountain sickness between budesonide and placebo.
    Time Frame
    During 18 hours at elevation compared to baseline.
    Title
    Changes in Gene regulation
    Description
    Comparison of gene regulation involved in acclimatization and altitude illness.
    Time Frame
    During 18 hours at elevation compared to baseline.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    21 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: healthy, altitude naive, 21-40 years old Exclusion Criteria: smokers pregnancy hx of asthma current inhaled steroid use those with diseases or disorders known to be affected by hypoxia or the drugs used in this study such as migraine or other chronic headaches, sickle cell trait or disease, or diabetes history of significant head injury or seizures taking any medication (over-the-counter or prescription) or herbal supplements a known hypersensitivity reaction to budesonide inability to be headache-free when consuming the amount of caffeine in two six ounce cups of coffee or less per day exposure to high altitude above 2000m in the previous 1 month or those who have been on an airline flight over six hours (Airplane cabins are pressurized to an elevation that can approximate exposure to high altitude)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ryan Paterson, MD, DiMM
    Organizational Affiliation
    University of Colorado, Denver
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Inhaled Budesonide for Altitude Illness Prevention

    We'll reach out to this number within 24 hrs